Skip to content. Skip to navigation
Personal tools
  Members Area  

ANZCA

Sections
You are here: Home Events ANZCA Annual Scientific Meetings 2008 ASM Abstracts Remifentanil postconditioning attenuates cardiac ischaemia-reperfusion injury in vivo
Navigation
News
24-08-2008
New drug
A new drug has just been approved for use in Australia. SITAGLIPTIN (Januvia) is an oral drug for type 2 Diabetes mellitus. It is a new class of drug, a dipeptidyl peptidase (DPP-4) inhibitor. Sitagliptin is an 'incretin enhancer' that increases the levels of active incretin by inhibiting their metabolism by DPP-4, thus prolonging their effect in stimulating insulin release and decreasing glucagon secretion.
24-08-2008
The latest ANZCA e-newsletter has been emailed
The latest edition of ANZCA’s e-newsletter has now been emailed to Fellows, trainees and ANZCA staff.
21-08-2008
Fellowship Affairs
The first meeting of the Fellowship Affairs Committee was held on Friday, 15 August 2008. Chaired by Dr Margaret Cowling, the Committee oversees all matters directly pertinent to Fellows, including CPD, annual scientific meetings, Regional CME and SIG events, communications and professional issues
20-08-2008
RFT for Australian Clinical Quality Registries pilot projects
The Australian Commission on Safety and Quality in Health Care is seeking tenders from relevant organisations to test and validate the draft 'Operating Principles and Technical Standards for Australian Clinical Quality Registries'.
20-08-2008
Electricity & greenhouse emissions
You might wonder whether turning off the lights when not required actually saves energy. Thanks to the efforts of College staff, we have saved a massive 15 per cent greenhouse gas emissions over the last six months compared to last year. A lot of this can be attributed to turning off lights and switching to energy efficient flourescent light globes. The impact has been significant.
More news…
 
Document Actions

Remifentanil postconditioning attenuates cardiac ischaemia-reperfusion injury in vivo

Gordon Wong, Li Rui, Michael Irwin

University of Hong Kong, Hong Kong SAR

Introduction: Remifentanil has previously been demonstrated to precondition the heart.1 Ischaemic post conditioning (IPoC) has been shown to involve opioid receptors (ORs). 2 This study investigates whether remifentanil confers cardioprotection when given after the start of the index ischaemic event.

Methods: Experiments were performed using the open chest rat model where 30 minutes of ischaemia was induced followed by 2 hours reperfusion. Prior to final reperfusion, the rats received either remifentanil postconditioning (RPoC) (5 mins at 20ug/kg/min), or IPoC (3 cycles of 10-s reperfusion interspersed with 10-s ischemia). These procedures were repeated in the presence of specific kappa OR antagonist nor-binaltorphimine (nBNI) or mu OR antagonist naltrindole (NTD), administered 10 mins before the respective postconditioning manoeuvres. The hearts were then excised and infarct size (IS) was determined and expressed as a percentage of the area at risk (AAR).

Results: Both RPoc and IPoc reduced IS /AAR to a similar extent when compared to control (p<0.05). This protective effect was abolished by the prior administration of any one the antagonists. Sole administration of the antagonists during ischaemia had no effect on the infarct size.


Group
CON RPoC IPoC IPoC+ NTD IPoC+ nBNI RPoC+ NTD RPoC+ nBNI NTD nBNI

n =

6 7 6 6 7 6 6 6 7
IS/AAR % 54.8 38.6 40.1 54.2 48.6 53.5 47.5 54.3 49.8
± SD 6.8 5.8 6.3 5.4 6.6 3.0 5.3 4.9 6.6

Conclusions: Remifentanil confers cardiac protection when given either before the ischaemic event or just before reperfusion.

1 Zhang et al Anesthesiology 2004; 2Youngho Jang et al Anesthesiology 2008.